Dihydropyridine calcium channel blockers and the progression of parkinsonism.
Identifieur interne : 000A88 ( PubMed/Checkpoint ); précédent : 000A87; suivant : 000A89Dihydropyridine calcium channel blockers and the progression of parkinsonism.
Auteurs : Connie Marras [Canada] ; Andrea Gruneir ; Paula Rochon ; Xuesong Wang ; Geoff Anderson ; Jonathan Brotchie ; Chaim M. Bell ; Susan Fox ; Peter C. AustinSource :
- Annals of neurology [ 1531-8249 ] ; 2012.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Calcium Channel Blockers (therapeutic use), Cohort Studies, Dihydropyridines (therapeutic use), Disease Progression, Female, Humans, Hypertension (drug therapy), Hypertension (epidemiology), Hypertension (pathology), Male, Parkinsonian Disorders (drug therapy), Parkinsonian Disorders (epidemiology), Parkinsonian Disorders (pathology), Retrospective Studies.
- MESH :
- chemical , therapeutic use : Calcium Channel Blockers, Dihydropyridines.
- drug therapy : Hypertension, Parkinsonian Disorders.
- epidemiology : Hypertension, Parkinsonian Disorders.
- pathology : Hypertension, Parkinsonian Disorders.
- Aged, Aged, 80 and over, Cohort Studies, Disease Progression, Female, Humans, Male, Retrospective Studies.
Abstract
A study was undertaken to test the association between dihydropyridine calcium channel blocker use and the time to important milestones of disease progression among patients with parkinsonism.
DOI: 10.1002/ana.22616
PubMed: 22451203
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:22451203Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dihydropyridine calcium channel blockers and the progression of parkinsonism.</title><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name><affiliation wicri:level="4"><nlm:affiliation>Division of Neurology, Toronto Western Hospital, and University of Toronto, Toronto, Ontario, Canada. cmarras@uhnresearch.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, Toronto Western Hospital, and University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Gruneir, Andrea" sort="Gruneir, Andrea" uniqKey="Gruneir A" first="Andrea" last="Gruneir">Andrea Gruneir</name></author><author><name sortKey="Rochon, Paula" sort="Rochon, Paula" uniqKey="Rochon P" first="Paula" last="Rochon">Paula Rochon</name></author><author><name sortKey="Wang, Xuesong" sort="Wang, Xuesong" uniqKey="Wang X" first="Xuesong" last="Wang">Xuesong Wang</name></author><author><name sortKey="Anderson, Geoff" sort="Anderson, Geoff" uniqKey="Anderson G" first="Geoff" last="Anderson">Geoff Anderson</name></author><author><name sortKey="Brotchie, Jonathan" sort="Brotchie, Jonathan" uniqKey="Brotchie J" first="Jonathan" last="Brotchie">Jonathan Brotchie</name></author><author><name sortKey="Bell, Chaim M" sort="Bell, Chaim M" uniqKey="Bell C" first="Chaim M" last="Bell">Chaim M. Bell</name></author><author><name sortKey="Fox, Susan" sort="Fox, Susan" uniqKey="Fox S" first="Susan" last="Fox">Susan Fox</name></author><author><name sortKey="Austin, Peter C" sort="Austin, Peter C" uniqKey="Austin P" first="Peter C" last="Austin">Peter C. Austin</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22451203</idno><idno type="pmid">22451203</idno><idno type="doi">10.1002/ana.22616</idno><idno type="wicri:Area/PubMed/Corpus">000A92</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A92</idno><idno type="wicri:Area/PubMed/Curation">000A92</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A92</idno><idno type="wicri:Area/PubMed/Checkpoint">000A92</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A92</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dihydropyridine calcium channel blockers and the progression of parkinsonism.</title><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name><affiliation wicri:level="4"><nlm:affiliation>Division of Neurology, Toronto Western Hospital, and University of Toronto, Toronto, Ontario, Canada. cmarras@uhnresearch.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, Toronto Western Hospital, and University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Gruneir, Andrea" sort="Gruneir, Andrea" uniqKey="Gruneir A" first="Andrea" last="Gruneir">Andrea Gruneir</name></author><author><name sortKey="Rochon, Paula" sort="Rochon, Paula" uniqKey="Rochon P" first="Paula" last="Rochon">Paula Rochon</name></author><author><name sortKey="Wang, Xuesong" sort="Wang, Xuesong" uniqKey="Wang X" first="Xuesong" last="Wang">Xuesong Wang</name></author><author><name sortKey="Anderson, Geoff" sort="Anderson, Geoff" uniqKey="Anderson G" first="Geoff" last="Anderson">Geoff Anderson</name></author><author><name sortKey="Brotchie, Jonathan" sort="Brotchie, Jonathan" uniqKey="Brotchie J" first="Jonathan" last="Brotchie">Jonathan Brotchie</name></author><author><name sortKey="Bell, Chaim M" sort="Bell, Chaim M" uniqKey="Bell C" first="Chaim M" last="Bell">Chaim M. Bell</name></author><author><name sortKey="Fox, Susan" sort="Fox, Susan" uniqKey="Fox S" first="Susan" last="Fox">Susan Fox</name></author><author><name sortKey="Austin, Peter C" sort="Austin, Peter C" uniqKey="Austin P" first="Peter C" last="Austin">Peter C. Austin</name></author></analytic><series><title level="j">Annals of neurology</title><idno type="eISSN">1531-8249</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Calcium Channel Blockers (therapeutic use)</term><term>Cohort Studies</term><term>Dihydropyridines (therapeutic use)</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Hypertension (drug therapy)</term><term>Hypertension (epidemiology)</term><term>Hypertension (pathology)</term><term>Male</term><term>Parkinsonian Disorders (drug therapy)</term><term>Parkinsonian Disorders (epidemiology)</term><term>Parkinsonian Disorders (pathology)</term><term>Retrospective Studies</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Calcium Channel Blockers</term><term>Dihydropyridines</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypertension</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Hypertension</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Hypertension</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Cohort Studies</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Male</term><term>Retrospective Studies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A study was undertaken to test the association between dihydropyridine calcium channel blocker use and the time to important milestones of disease progression among patients with parkinsonism.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22451203</PMID><DateCreated><Year>2012</Year><Month>03</Month><Day>27</Day></DateCreated><DateCompleted><Year>2012</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2012</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann. Neurol.</ISOAbbreviation></Journal><ArticleTitle>Dihydropyridine calcium channel blockers and the progression of parkinsonism.</ArticleTitle><Pagination><MedlinePgn>362-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.22616</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">A study was undertaken to test the association between dihydropyridine calcium channel blocker use and the time to important milestones of disease progression among patients with parkinsonism.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data were obtained from Ontario's health care administrative databases. Within a cohort of hypertensive individuals older than 65 years who developed parkinsonism, we examined the effect of the length of exposure to less brain-penetrant dihydropyridines (amlodipine) and more brain-penetrant dihydropyridines (eg, nifedipine, felodipine) on parkinsonism milestones as measured by time to requiring drug treatment for parkinsonism, nursing home admission, and death.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 4,733 hypertensive individuals with parkinsonism, longer treatment with any dihydropyridine was associated with a decreased risk of each of the 3 outcomes. There was no difference, however, between amlodipine (adjusted hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.42-0.50 for initiation of drug treatment; HR, 0.68; 95% CI, 0.63-0.73 for application for nursing home admission; and HR, 0.75; 95% CI, 0.70-0.80 for death) and nonamlodipine dihydropyridines (adjusted HRs [95% CIs], 0.45 [0.39-0.53], 0.74 [0.67-0.81], and 0.74 [0.64-0.85] for the 3 milestones, respectively).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">We found no specific beneficial effect of treatment with brain-penetrant dihydropyridines on delaying parkinsonism progression milestones. Dihydropyridine calcium channel blockers are unlikely to have a clinically significant effect on the course of parkinsonism, particularly Parkinson disease, in the doses used to treat hypertension.</AbstractText><CopyrightInformation>Copyright © 2012 American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marras</LastName><ForeName>Connie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Neurology, Toronto Western Hospital, and University of Toronto, Toronto, Ontario, Canada. cmarras@uhnresearch.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gruneir</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rochon</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xuesong</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Geoff</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Brotchie</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Chaim M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Austin</LastName><ForeName>Peter C</ForeName><Initials>PC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOP93678</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004095">Dihydropyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>7M8K3P6I89</RegistryNumber><NameOfSubstance UI="C038806">1,4-dihydropyridine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004095" MajorTopicYN="N">Dihydropyridines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22451203</ArticleId><ArticleId IdType="doi">10.1002/ana.22616</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><noCountry><name sortKey="Anderson, Geoff" sort="Anderson, Geoff" uniqKey="Anderson G" first="Geoff" last="Anderson">Geoff Anderson</name><name sortKey="Austin, Peter C" sort="Austin, Peter C" uniqKey="Austin P" first="Peter C" last="Austin">Peter C. Austin</name><name sortKey="Bell, Chaim M" sort="Bell, Chaim M" uniqKey="Bell C" first="Chaim M" last="Bell">Chaim M. Bell</name><name sortKey="Brotchie, Jonathan" sort="Brotchie, Jonathan" uniqKey="Brotchie J" first="Jonathan" last="Brotchie">Jonathan Brotchie</name><name sortKey="Fox, Susan" sort="Fox, Susan" uniqKey="Fox S" first="Susan" last="Fox">Susan Fox</name><name sortKey="Gruneir, Andrea" sort="Gruneir, Andrea" uniqKey="Gruneir A" first="Andrea" last="Gruneir">Andrea Gruneir</name><name sortKey="Rochon, Paula" sort="Rochon, Paula" uniqKey="Rochon P" first="Paula" last="Rochon">Paula Rochon</name><name sortKey="Wang, Xuesong" sort="Wang, Xuesong" uniqKey="Wang X" first="Xuesong" last="Wang">Xuesong Wang</name></noCountry><country name="Canada"><region name="Ontario"><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A88 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000A88 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:22451203
|texte= Dihydropyridine calcium channel blockers and the progression of parkinsonism.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:22451203" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |